Intracranial Hypertension Recurrence Risk After Wean of Intracranial Pressure-Lowering Medication.

The proportion of children with recurrent signs and symptoms of intracranial hypertension after medication wean has been reported to be between 18% and 50%. Few studies have reported intracranial hypertension recurrence risk in children while adjusting for each individual's observed follow-up time after medication wean. In addition, the role of intracranial hypertension etiology on the risk of disease recurrence has not been widely studied. The medical charts of patients with intracranial hypertension treated with intracranial pressure-lowering medication were analyzed retrospectively for disease recurrence. Baseline characteristics from diagnosis were recorded in addition to information regarding duration of therapy, medication wean, and recurrence. Survival analyses as well as Poisson regression models with time under observation as an offset were performed. One hundred and thirty-three patients were included in the study. The cumulative risk of intracranial hypertension recurrence increased rapidly within the first six months after medication wean and was 1.5% at one month, 9.5% at three months, and 20% at six months. This risk leveled off near 12 to 18 months. While the cumulative risk of intracranial hypertension recurrence increases most dramatically within the first six months after medication wean, it does not appear to taper until 12 to 18 months. Given the possibility of delayed or asymptomatic recurrences, long-term follow-up is ideal, although patients can likely be seen less frequently after the first 12 to 18 months after medication wean. Copyright © 2021 Elsevier Inc. All rights reserved.

Citation

Anastasia A Alex, Catherine O Jordan, Jason A Benedict, Shawn C Aylward, David L Rogers, Hilliary E Inger. Intracranial Hypertension Recurrence Risk After Wean of Intracranial Pressure-Lowering Medication. Pediatric neurology. 2021 Aug;121:40-44

Mesh Tags

Substances

PMID: 34153813

search → result